- Home
- EBC vs TLX Comparison
EBC vs TLX Comparison
Compare EBC & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBC | TLX |
|---|---|---|
| Founded | 1818 | 2015 |
| Country | United States | Australia |
| Employees | N/A | 1184 |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.6B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | EBC | TLX |
|---|---|---|
| Price | $22.67 | $10.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $22.70 | $21.13 |
| AVG Volume (30 Days) | ★ 4.2M | 181.0K |
| Earning Date | 04-23-2026 | 08-19-2026 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $134,091,000.00 | N/A |
| Revenue This Year | $80.92 | N/A |
| Revenue Next Year | $4.44 | N/A |
| P/E Ratio | ★ $78.10 | $150.33 |
| Revenue Growth | ★ 19.07 | N/A |
| 52 Week Low | $14.88 | $6.28 |
| 52 Week High | $23.54 | $14.81 |
Technical Indicators
Market Signals| Indicator | EBC | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 59.31 | 45.85 |
| Support Level | $19.12 | $10.06 |
| Resistance Level | $22.73 | $11.38 |
| Average True Range (ATR) | 0.53 | 0.27 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 56.27 | 17.25 |
Price Performance
Historical ComparisonAbout EBC Eastern Bankshares Inc.
Eastern Bankshares Inc is a commercial bank that caters its products and services to retail, commercial, and small business customers. Its diversified products and services include lending, deposit, wealth management, and insurance products. The company has one operating segment: Banking business, which offers a range of banking, lending, savings, and small business offerings, and its wealth management and trust operations.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.